期刊文献+

SEC-HPLC法测定rhTNK-tPA单链含量 被引量:3

SEC-HPLC chromatography method for determination of rhTNK-tPA's single-chain content
原文传递
导出
摘要 目的:测定重组人组织型纤溶酶原激活剂改构体(combinant human mutant-threonine mutant-asparagine mutant-lysine tissue type plasminogen activator,rhTNK-tPA)单链含量。方法:将样品用二硫苏糖醇(DTT)打开二硫键,采用分子排阻色谱(size-exclusion high performance liquid chromatograph,SEC-HPLC)法测定。色谱柱:Tsk-Gel2000SWxl;流动相:0.2 mol·L-1PB-0.1%SDS水溶液;流速:0.5 mL·min-1;检测波长:214 nm;柱温:23℃;检测时间:30 min。结果:试验精密度和重复性良好;分离度不低于1.1;3批rhTNK-tPA原液的单链含量分别为74.41%、75.39%、74.43%,3批成品的单链含量分别为73.82%、74.76%、74.91%。结论:本方法经方法学验证可用于rhTNK-tPA产品的常规检定。 Objective: To establish a method for the determination of the single chain content of recombinant human tenecteplase( TNK- tPA). Methods: Disulfide bond of the samples were first opened by dithiothreitol( DTT),and then the HPLC- SEC method was adopted for the analysis in this study. The column was Tsk- Gel2000 SWxl,and the mobile phase was consisted of 0. 2 mol·L- 1PB and 0. 1% SDS solution; The flow rate was 0. 5 mL·min- 1,the detection wavelength was set at 214 nm,and the column temperature was 23 ℃. The detection time was 30 min. Results: The precision and repeatability of the tests were very good,the resolution between the single chain and two- chain alteplase peaks was not less than 1. 1. The single chain content of rhTNK- tPA was 74. 41%,75. 39%,74. 43%( three batches of bulk) and 73. 82%,74. 76%,74. 91%( three batches of final products),respectively. Conclusion: The established method can be used for the routine quality control of rhTNK- tPA.
出处 《药物分析杂志》 CAS CSCD 北大核心 2014年第7期1208-1211,共4页 Chinese Journal of Pharmaceutical Analysis
基金 国家科技重大专项课题(2012ZX09304010)
关键词 重组人组织型纤溶酶原激活剂改构体 高效液相色谱 单链含量 recombinant human tenectelase SEC-HPLC the single chain content
  • 相关文献

参考文献11

  • 1Rabasseda X. Tenecteplase (TNK tissue plasminogen activator):a new fibrinolytic for the acute treatment of myocardial infarction [J]. Drugs Today (Barc), 2001, 11(37):749.
  • 2奉涛.溶栓药物的临床应用及其进展[J].临床合理用药杂志,2011,4(12):145-146. 被引量:14
  • 3王贵鑫,吕莉.溶栓药物的药理学研究进展[J].血栓与止血学,2011,17(5):234-236. 被引量:16
  • 4WANG Jun-zhi(王军志). Research, Development and Quality Control of Bio-pharmceutics(生物技术药物研究发展和质量控制)[M].Beijing(北京):Science Press(科学出版社),2007:727.
  • 5吴丹明,张立魁.溶栓药物分类及合理应用[J].中国实用外科杂志,2011,31(12):1136-1137. 被引量:15
  • 6Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial [J]. Circulation, 1997, 95(2):351.
  • 7Iamach J.Thrombolytic bolus may give acute MI a thombolytic ride[J].Phys Weekly,1999,16(15):122.
  • 8Elliott MA,David MA,Carolyn HM,et al.Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction[J]. New Eng J Med,2006,354(14):1477.
  • 9Venu M,Robert AH,Judith SH,et al.Thrombolysis and adjunctive therapy in acute myocardial infarction:The seventh ACCP conference on antithrombotic and thrombolytic therapy[J].Cardiopulm Crit Care J,2004,126(3 Suppl):549.
  • 10EP 7.0[S]. 2008:1170.

二级参考文献35

共引文献37

同被引文献44

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部